Enoxaparin Reduces Occurrence of Venous Thromboembolic Events

Enoxaparin taken post-radical cystectomy may prevent the occurrence of venous thromboembolic events (VTEs), according to a study published in The Journal of Urology.¹

Among 402 patients undergoing radical cystectomy, researchers evaluated whether heparin, the treatment typically used to prevent VTEs, is superior to heparin given normally plus enoxaparin taken postoperatively every day until 28 days after discharge.

Members of the 2 groups were of a similar age, had a similar body mass index and smoking history, and were at a similar stage of disease; 234 received heparin only and 168 received the added enoxaparin.

Members of the enoxaparin group were less than half as likely to have VTEs within 90 days post-operation: 28 (12%) patients had a VTE with heparin only, and 9 (5%) patients had a VTE with heparin plus enoxaparin.

It was concluded that enoxaparin reduces the rate of VTEs among patients undergoing radical cystectomy; no increased bleeding risk was observed.

Reference

1. Pariser JJ, Pearce SM, Anderson BB, et al. Extended-duration enoxaparin decreases the rate of venous thromboembolic events after radical cystectomy compared to inpatient-only subcutaneous heparin. J Urol. In press.